Archive for the ‘Regulatory Medical Writing’ Category

๐’๐ฒ๐ง๐ž๐ซ๐ ๐ข๐ฌ๐ญ๐ข๐œ ๐“๐จ๐ฆ๐จ๐ ๐ซ๐š๐ฉ๐ก๐ฒ: ๐‘๐”๐’-๐๐€๐“ ๐”๐ง๐ข๐Ÿ๐ข๐ž๐ฌ ๐’๐ญ๐ซ๐ฎ๐œ๐ญ๐ฎ๐ซ๐š๐ฅ ๐š๐ง๐ ๐…๐ฎ๐ง๐œ๐ญ๐ข๐จ๐ง๐š๐ฅ ๐ˆ๐ฆ๐š๐ ๐ข๐ง๐  ๐ข๐ง ๐š ๐’๐ข๐ง๐ ๐ฅ๐ž, ๐‘๐š๐ฉ๐ข๐ ๐Œ๐จ๐๐š๐ฅ๐ข๐ญ๐ฒ (Colored Ultrasound Imaging)

Posted by Michael A. S. Guth on January 28th, 2026

A significant advancement in medical imaging is detailed in the January 16 issue ofย Nature Biomedical Engineering. Researchers from Caltech and USC have developedย Rotational Ultrasound and Photoacoustic Tomography (RUS-PAT), a novel hybrid technique that overcomes the fundamental limitations of standalone ultrasound and photoacoustic imaging to deliver rapid, co-registered 3D structural and functional data. The Core Innovation:ย Traditional […]

Posted in Regulatory Medical Writing No Comments »
Read More »

ฮฑ-๐’๐ฒ๐ง๐ฎ๐œ๐ฅ๐ž๐ข๐ง ๐ฉ๐š๐ญ๐ก๐จ๐ฅ๐จ๐ ๐ข๐œ๐š๐ฅ ๐š๐ ๐ ๐ซ๐ž๐ ๐š๐ญ๐ข๐จ๐ง ๐ข๐ง๐ญ๐จ ๐ข๐ง๐ฌ๐จ๐ฅ๐ฎ๐›๐ฅ๐ž ๐Ÿ๐ข๐›๐ซ๐ข๐ฅ๐ฌ (๐Ÿ๐จ๐ซ๐ฆ๐ข๐ง๐  ๐‹๐ž๐ฐ๐ฒ ๐›๐จ๐๐ข๐ž๐ฌ)

Posted by Michael A. S. Guth on January 28th, 2026

๐Œ๐ฒ ๐ซ๐ž๐ฌ๐ž๐š๐ซ๐œ๐ก ๐ฐ๐จ๐ซ๐ค ๐จ๐ง ๐€๐ฅ๐ณ๐ก๐ž๐ข๐ฆ๐ž๐ซ’๐ฌ ๐๐ข๐ฌ๐ž๐š๐ฌ๐ž ๐ญ๐จ๐๐š๐ฒ ๐œ๐จ๐ฏ๐ž๐ซ๐ฌ ๐ฆ๐š๐ง๐ฒ ๐ญ๐จ๐ฉ๐ข๐œ๐ฌ ๐ข๐ง๐œ๐ฅ๐ฎ๐๐ข๐ง๐  ฮฑ-๐’๐ฒ๐ง๐ฎ๐œ๐ฅ๐ž๐ข๐ง, ๐š ๐Ÿ๐Ÿ’๐ŸŽ-๐š๐ฆ๐ข๐ง๐จ ๐š๐œ๐ข๐ ๐ฉ๐ซ๐จ๐ญ๐ž๐ข๐ง ๐ฉ๐ซ๐ข๐ฆ๐š๐ซ๐ข๐ฅ๐ฒ ๐Ÿ๐จ๐ฎ๐ง๐ ๐ข๐ง ๐ง๐ž๐ฎ๐ซ๐š๐ฅ ๐ญ๐ข๐ฌ๐ฌ๐ฎ๐ž (๐ฌ๐ฉ๐ž๐œ๐ข๐Ÿ๐ข๐œ๐š๐ฅ๐ฅ๐ฒ ๐ฉ๐ซ๐ž๐ฌ๐ฒ๐ง๐š๐ฉ๐ญ๐ข๐œ ๐ญ๐ž๐ซ๐ฆ๐ข๐ง๐š๐ฅ๐ฌ). ฮฑ-๐’๐ฒ๐ง๐ฎ๐œ๐ฅ๐ž๐ข๐ง ๐ฉ๐ฅ๐š๐ฒ๐ฌ ๐š ๐ค๐ž๐ฒ ๐ซ๐จ๐ฅ๐ž ๐ข๐ง ๐ฌ๐ฒ๐ง๐š๐ฉ๐ญ๐ข๐œ ๐ฏ๐ž๐ฌ๐ข๐œ๐ฅ๐ž ๐ญ๐ซ๐š๐Ÿ๐Ÿ๐ข๐œ๐ค๐ข๐ง๐ , ๐ง๐ž๐ฎ๐ซ๐จ๐ญ๐ซ๐š๐ง๐ฌ๐ฆ๐ข๐ญ๐ญ๐ž๐ซ ๐ซ๐ž๐ฅ๐ž๐š๐ฌ๐ž, ๐š๐ง๐ ๐ฉ๐จ๐ญ๐ž๐ง๐ญ๐ข๐š๐ฅ๐ฅ๐ฒ ๐ง๐ž๐ฎ๐ซ๐จ๐ง๐š๐ฅ ๐ฌ๐ฎ๐ซ๐ฏ๐ข๐ฏ๐š๐ฅ. ๐–๐ก๐ข๐ฅ๐ž ๐ข๐ญ๐ฌ ๐ž๐ฑ๐š๐œ๐ญ ๐ฉ๐ก๐ฒ๐ฌ๐ข๐จ๐ฅ๐จ๐ ๐ข๐œ๐š๐ฅ ๐Ÿ๐ฎ๐ง๐œ๐ญ๐ข๐จ๐ง ๐ซ๐ž๐ฆ๐š๐ข๐ง๐ฌ ๐ฎ๐ง๐๐ž๐ซ ๐ข๐ง๐ฏ๐ž๐ฌ๐ญ๐ข๐ ๐š๐ญ๐ข๐จ๐ง, ๐ข๐ญ๐ฌ ๐ฉ๐š๐ญ๐ก๐จ๐ฅ๐จ๐ ๐ข๐œ๐š๐ฅ ๐š๐ ๐ ๐ซ๐ž๐ ๐š๐ญ๐ข๐จ๐ง ๐ข๐ง๐ญ๐จ ๐ข๐ง๐ฌ๐จ๐ฅ๐ฎ๐›๐ฅ๐ž ๐Ÿ๐ข๐›๐ซ๐ข๐ฅ๐ฌ (๐Ÿ๐จ๐ซ๐ฆ๐ข๐ง๐  ๐‹๐ž๐ฐ๐ฒ […]

Posted in Neuroplasticity, Regulatory Medical Writing No Comments »
Read More »

The 2026 Transatlantic Market Access Pivot: An Architectural Framework

Posted by Michael A. S. Guth on January 22nd, 2026

Market Access 2026: Transatlantic Pivot Toolkit A Strategic Resource for Founders & VCs Navigating the EU JSC & NHS Threshold Shifts Prepared by Michael A. S. Guth, Ph.D., J.D. | Strategic Systems Architect for High-Complexity Biologics, Drugs, and Device combinations Executive Summary The 2026 regulatory-access landscape has fundamentally shifted with two parallel developments: EU’s Joint […]

Posted in AI Governance, Pharma and Medical Device, Regulatory Medical Writing No Comments »
Read More »

๐“๐ก๐ž ๐๐จ๐ฅ๐ฒ๐ฆ๐ž๐ซ-๐๐ซ๐จ๐ญ๐ž๐ข๐ง ๐‡๐ฒ๐ฉ๐จ๐ญ๐ก๐ž๐ฌ๐ข๐ฌ: ๐€๐ซ๐ž ๐Œ๐ข๐œ๐ซ๐จ๐ฉ๐ฅ๐š๐ฌ๐ญ๐ข๐œ๐ฌ ๐€๐œ๐œ๐ž๐ฅ๐ž๐ซ๐š๐ญ๐ข๐ง๐  ๐๐ž๐ฎ๐ซ๐จ๐๐ž๐ ๐ž๐ง๐ž๐ซ๐š๐ญ๐ข๐จ๐ง?

Posted by Michael A. S. Guth on January 10th, 2026

๐€๐ญ ๐ญ๐ก๐ž ๐ˆ๐ง๐ฌ๐ญ๐ข๐ญ๐ฎ๐ญ๐ž ๐จ๐Ÿ ๐๐ž๐ฎ๐ซ๐จ๐ฉ๐ฅ๐š๐ฌ๐ญ๐ข๐œ๐ข๐ญ๐ฒ ๐‘๐ž๐ฌ๐ž๐š๐ซ๐œ๐ก, ๐ฐ๐ž ๐š๐ซ๐ž ๐œ๐ฅ๐จ๐ฌ๐ž๐ฅ๐ฒ ๐ฆ๐จ๐ง๐ข๐ญ๐จ๐ซ๐ข๐ง๐  ๐š ๐ญ๐ซ๐จ๐ฎ๐›๐ฅ๐ข๐ง๐  ๐ง๐ž๐ฐ ๐Ÿ๐ซ๐จ๐ง๐ญ๐ข๐ž๐ซ ๐ข๐ง ๐ž๐ง๐ฏ๐ข๐ซ๐จ๐ง๐ฆ๐ž๐ง๐ญ๐š๐ฅ ๐ง๐ž๐ฎ๐ซ๐จ๐ฌ๐œ๐ข๐ž๐ง๐œ๐ž: ๐ญ๐ก๐ž ๐๐ข๐ฌ๐œ๐จ๐ฏ๐ž๐ซ๐ฒ ๐จ๐Ÿ ๐ง๐š๐ง๐จ๐ฉ๐ฅ๐š๐ฌ๐ญ๐ข๐œ๐ฌ ๐œ๐ซ๐จ๐ฌ๐ฌ๐ข๐ง๐  ๐ญ๐ก๐ž ๐›๐ฅ๐จ๐จ๐-๐›๐ซ๐š๐ข๐ง ๐›๐š๐ซ๐ซ๐ข๐ž๐ซ (๐๐๐). While the physical presence of these synthetic polymers is confirmed, a critical hypothesis is emerging among researchers: Could microplastics be acting as a structural “scaffold” for beta-amyloid plaques? The […]

Posted in Neuroplasticity, Regulatory Medical Writing Comments Off on ๐“๐ก๐ž ๐๐จ๐ฅ๐ฒ๐ฆ๐ž๐ซ-๐๐ซ๐จ๐ญ๐ž๐ข๐ง ๐‡๐ฒ๐ฉ๐จ๐ญ๐ก๐ž๐ฌ๐ข๐ฌ: ๐€๐ซ๐ž ๐Œ๐ข๐œ๐ซ๐จ๐ฉ๐ฅ๐š๐ฌ๐ญ๐ข๐œ๐ฌ ๐€๐œ๐œ๐ž๐ฅ๐ž๐ซ๐š๐ญ๐ข๐ง๐  ๐๐ž๐ฎ๐ซ๐จ๐๐ž๐ ๐ž๐ง๐ž๐ซ๐š๐ญ๐ข๐จ๐ง?
Read More »

๐—”๐—ฅ๐—˜ ๐—ช๐—˜ ๐—ก๐—ข๐—ช ๐—œ๐—ก ๐—ง๐—›๐—˜ ๐—•๐—จ๐—ฆ๐—œ๐—ก๐—˜๐—ฆ๐—ฆ ๐—ข๐—™ ๐—ฅ๐—˜๐—œ๐— ๐—•๐—จ๐—ฅ๐—ฆ๐—œ๐—ก๐—š “๐—ก๐—ข๐—ก-๐—œ๐—ก๐—™๐—˜๐—ฅ๐—œ๐—ข๐—ฅ?”

Posted by Michael A. S. Guth on January 8th, 2026

๐—–๐—ต๐—ฎ๐—น๐—น๐—ฒ๐—ป๐—ด๐—ฒ ๐˜๐—ต๐—ฒ ๐—ฝ๐—ฟ๐—ฒ๐—บ๐—ถ๐˜€๐—ฒ ๐—ผ๐—ณ ๐—ฐ๐—ฒ๐—น๐—ฒ๐—ฏ๐—ฟ๐—ฎ๐˜๐—ถ๐—ป๐—ด ๐—ป๐—ผ๐—ป-๐—ถ๐—ป๐—ณ๐—ฒ๐—ฟ๐—ถ๐—ผ๐—ฟ๐—ถ๐˜๐˜† ๐—ถ๐—ป ๐—ฎ ๐—บ๐—ฎ๐˜๐˜‚๐—ฟ๐—ฒ ๐—บ๐—ฎ๐—ฟ๐—ธ๐—ฒ๐˜ ๐—ฎ๐—ป๐—ฑ ๐—พ๐˜‚๐—ฒ๐˜€๐˜๐—ถ๐—ผ๐—ป ๐˜๐—ต๐—ฒ ๐—ต๐—ฒ๐—ฎ๐—น๐˜๐—ต ๐—ฒ๐—ฐ๐—ผ๐—ป๐—ผ๐—บ๐—ถ๐—ฐ ๐—ฟ๐—ฎ๐˜๐—ถ๐—ผ๐—ป๐—ฎ๐—น๐—ฒ. ๐—›๐—ฒ๐—ฎ๐—ฑ๐—น๐—ถ๐—ป๐—ฒ: ๐—” ๐—ก๐—ฒ๐˜„ ๐—ฃ๐—ถ๐—น๐—น ๐—ณ๐—ผ๐—ฟ ๐—›๐—œ๐—ฉ: ๐—œ๐—ป๐—ฐ๐—ฟ๐—ฒ๐—บ๐—ฒ๐—ป๐˜๐—ฎ๐—น ๐—–๐—ต๐—ฎ๐—ป๐—ด๐—ฒ ๐—ผ๐—ฟ ๐—ฃ๐—ฟ๐—ถ๐—ฐ๐—ฒ๐—ฑ ๐—ฎ๐˜€ ๐—œ๐—ป๐—ป๐—ผ๐˜ƒ๐—ฎ๐˜๐—ถ๐—ผ๐—ป? ๐—š๐—ถ๐—น๐—ฒ๐—ฎ๐—ฑ’๐˜€ ๐—”๐—ฅ๐—ง๐—œ๐—ฆ๐—ง๐—ฅ๐—ฌ-๐Ÿฎ ๐˜๐—ฟ๐—ถ๐—ฎ๐—น ๐˜€๐—ต๐—ผ๐˜„๐˜€ ๐—ถ๐˜๐˜€ ๐—ป๐—ฒ๐˜„ ๐—•๐—œ๐—–/๐—Ÿ๐—˜๐—ก ๐˜€๐—ถ๐—ป๐—ด๐—น๐—ฒ-๐˜๐—ฎ๐—ฏ๐—น๐—ฒ๐˜ ๐—ฟ๐—ฒ๐—ด๐—ถ๐—บ๐—ฒ๐—ป ๐—ถ๐˜€ ๐—ป๐—ผ๐—ป-๐—ถ๐—ป๐—ณ๐—ฒ๐—ฟ๐—ถ๐—ผ๐—ฟ ๐˜๐—ผ ๐—ถ๐˜๐˜€ ๐—ผ๐˜„๐—ป ๐—ฏ๐—น๐—ผ๐—ฐ๐—ธ๐—ฏ๐˜‚๐˜€๐˜๐—ฒ๐—ฟ, ๐—•๐—œ๐—ž๐—ง๐—”๐—ฅ๐—ฉ๐—ฌ, ๐—ณ๐—ผ๐—ฟ ๐˜ƒ๐—ถ๐—ฟ๐—ผ๐—น๐—ผ๐—ด๐—ถ๐—ฐ๐—ฎ๐—น๐—น๐˜† ๐˜€๐˜‚๐—ฝ๐—ฝ๐—ฟ๐—ฒ๐˜€๐˜€๐—ฒ๐—ฑ ๐—ฝ๐—ฎ๐˜๐—ถ๐—ฒ๐—ป๐˜๐˜€. ๐—ง๐—ต๐—ฒ ๐˜€๐—ฐ๐—ถ๐—ฒ๐—ป๐—ฐ๐—ฒ ๐—ถ๐˜€ ๐˜€๐—ผ๐˜‚๐—ป๐—ฑ, ๐—ฏ๐˜‚๐˜ ๐—ถ๐˜ ๐—ฝ๐—ฟ๐—ผ๐—บ๐—ฝ๐˜๐˜€ […]

Posted in Pharma and Medical Device, Regulatory Medical Writing Comments Off on ๐—”๐—ฅ๐—˜ ๐—ช๐—˜ ๐—ก๐—ข๐—ช ๐—œ๐—ก ๐—ง๐—›๐—˜ ๐—•๐—จ๐—ฆ๐—œ๐—ก๐—˜๐—ฆ๐—ฆ ๐—ข๐—™ ๐—ฅ๐—˜๐—œ๐— ๐—•๐—จ๐—ฅ๐—ฆ๐—œ๐—ก๐—š “๐—ก๐—ข๐—ก-๐—œ๐—ก๐—™๐—˜๐—ฅ๐—œ๐—ข๐—ฅ?”
Read More »

A New Anchor in RRMM: Decoding the Practice-Changing MajesTEC-3 Data for Tec-Dara

Posted by Michael A. S. Guth on January 8th, 2026

The MajesTEC-3 results for teclistamab + daratumumab (Tec-Dara)ย in relapsed/refractory multiple myeloma (RRMM) aren’t just an incremental gainโ€”they represent a potential paradigm shift. The FDA’s concurrent award of aย priority review voucherย underscores its transformative potential. Let’s break down the data that’s changing the standard of care: ๐Ÿ”ฌ Unprecedented Efficacy in the 1-3 Prior Lines Setting: โ€ขย PFS:ย Hazard Ratio […]

Posted in Pharma and Medical Device, Regulatory Medical Writing Comments Off on A New Anchor in RRMM: Decoding the Practice-Changing MajesTEC-3 Data for Tec-Dara
Read More »

One Drug, Two Paths: Decoding Novartis’s Ianalumab Strategy

Posted by Michael A. S. Guth on January 8th, 2026

Following up on my last post: the key to understanding a drug’s potential isn’t just its mechanismโ€”it’s how the sponsor chooses to prove it. Comparing the ianalumab trials side-by-side reveals a brilliant, bifurcated strategy. Trial Aspect Sjรถgren’s (NEPTUNUS-1) Refractory ITP (Phase 2) Phase Pivotal Phase 3 Signal-seeking Phase 2 Design Randomized, Double-blind, Placebo-controlled Open-label, Single-Arm […]

Posted in Regulatory Medical Writing Comments Off on One Drug, Two Paths: Decoding Novartis’s Ianalumab Strategy
Read More »

Why is the same drug ๐ˆ๐š๐ง๐š๐ฅ๐ฎ๐ฆ๐š๐› being tested in Sjรถgren’s Syndrome and Immune Thrombocytopenia?

Posted by Michael A. S. Guth on January 8th, 2026

๐–๐ก๐ฒ ๐ข๐ฌ ๐ญ๐ก๐ž ๐ฌ๐š๐ฆ๐ž ๐๐ซ๐ฎ๐  ๐›๐ž๐ข๐ง๐  ๐ญ๐ž๐ฌ๐ญ๐ž๐ ๐ข๐ง ๐’๐ฃรถ๐ ๐ซ๐ž๐ง’๐ฌ ๐’๐ฒ๐ง๐๐ซ๐จ๐ฆ๐ž ๐š๐ง๐ ๐ˆ๐ฆ๐ฆ๐ฎ๐ง๐ž ๐“๐ก๐ซ๐จ๐ฆ๐›๐จ๐œ๐ฒ๐ญ๐จ๐ฉ๐ž๐ง๐ข๐š? ๐ˆ’๐ฏ๐ž ๐›๐ž๐ž๐ง ๐๐ข๐ ๐ ๐ข๐ง๐  ๐ข๐ง๐ญ๐จ ๐ญ๐ก๐ž ๐œ๐ฅ๐ข๐ง๐ข๐œ๐š๐ฅ ๐ฉ๐ข๐ฉ๐ž๐ฅ๐ข๐ง๐ž ๐Ÿ๐จ๐ซ ๐ง๐จ๐ฏ๐ž๐ฅ ๐š๐ฎ๐ญ๐จ๐ข๐ฆ๐ฆ๐ฎ๐ง๐ž ๐ญ๐ก๐ž๐ซ๐š๐ฉ๐ข๐ž๐ฌ, ๐š๐ง๐ ๐๐จ๐ฏ๐š๐ซ๐ญ๐ข๐ฌ’๐ฌ ๐๐ž๐ฏ๐ž๐ฅ๐จ๐ฉ๐ฆ๐ž๐ง๐ญ ๐จ๐Ÿ ๐ข๐š๐ง๐š๐ฅ๐ฎ๐ฆ๐š๐› (๐•๐€๐˜๐Ÿ•๐Ÿ‘๐Ÿ”) ๐œ๐š๐ฎ๐ ๐ก๐ญ ๐ฆ๐ฒ ๐ž๐ฒ๐ž. ๐ˆ๐ญ’๐ฌ ๐š ๐๐€๐…๐…-๐‘ ๐ข๐ง๐ก๐ข๐›๐ข๐ญ๐จ๐ซ ๐ฐ๐ข๐ญ๐ก ๐š ๐๐ฎ๐š๐ฅ ๐ฆ๐ž๐œ๐ก๐š๐ง๐ข๐ฌ๐ฆ: ๐›๐ฅ๐จ๐œ๐ค๐ข๐ง๐  ๐-๐œ๐ž๐ฅ๐ฅ ๐ฌ๐ฎ๐ซ๐ฏ๐ข๐ฏ๐š๐ฅ ๐ฌ๐ข๐ ๐ง๐š๐ฅ๐ฌ ๐š๐ง๐ ๐๐ž๐ฉ๐ฅ๐ž๐ญ๐ข๐ง๐  ๐ฆ๐š๐ญ๐ฎ๐ซ๐ž ๐-๐œ๐ž๐ฅ๐ฅ๐ฌ. ๐“๐ก๐ž ๐ข๐ง๐ญ๐ž๐ซ๐ž๐ฌ๐ญ๐ข๐ง๐  ๐ฉ๐š๐ซ๐ญ? ๐๐จ๐ฏ๐š๐ซ๐ญ๐ข๐ฌ ๐ข๐ฌ ๐ซ๐ฎ๐ง๐ง๐ข๐ง๐  […]

Posted in Regulatory Medical Writing Comments Off on Why is the same drug ๐ˆ๐š๐ง๐š๐ฅ๐ฎ๐ฆ๐š๐› being tested in Sjรถgren’s Syndrome and Immune Thrombocytopenia?
Read More »

๐…๐ซ๐จ๐ฆ ๐€๐ฌ๐ฌ๐ข๐ฌ๐ญ๐š๐ง๐œ๐ž ๐ญ๐จ ๐€๐ ๐ž๐ง๐œ๐ฒ: ๐–๐ก๐ฒ ๐๐ซ๐ž๐œ๐ข๐ฌ๐ข๐จ๐ง ๐‚๐š๐ซ๐ž ๐†๐ข๐š๐ง๐ญ๐ฌ ๐๐ž๐ž๐ ๐‚๐จ๐ฆ๐›๐ข๐ง๐ž๐ ๐‘๐ž๐ ๐ฎ๐ฅ๐š๐ญ๐จ๐ซ๐ฒ/๐“๐ก๐ž๐ซ๐š๐ฉ๐ž๐ฎ๐ญ๐ข๐œ ๐€๐ซ๐ž๐š/๐€๐ˆ ๐’๐ค๐ข๐ฅ๐ฅ๐ž๐ ๐“๐š๐ฅ๐ž๐ง๐ญ

Posted by Michael A. S. Guth on January 3rd, 2026

๐“๐ก๐ž “๐๐ฎ๐ซ๐ฉ๐ฅ๐ž ๐’๐ช๐ฎ๐ข๐ซ๐ซ๐ž๐ฅ” ๐“๐š๐ฅ๐ž๐ง๐ญ ๐†๐š๐ฉ Recruiters often call this the โ€œpurple squirrelโ€ profile: a “unicorn” blending deep regulatory strategy, therapeutic area such as neurology research expertise, with a fundamental understanding of AI application.

Posted in AI Governance, Pharma and Medical Device, Regulatory Medical Writing Comments Off on ๐…๐ซ๐จ๐ฆ ๐€๐ฌ๐ฌ๐ข๐ฌ๐ญ๐š๐ง๐œ๐ž ๐ญ๐จ ๐€๐ ๐ž๐ง๐œ๐ฒ: ๐–๐ก๐ฒ ๐๐ซ๐ž๐œ๐ข๐ฌ๐ข๐จ๐ง ๐‚๐š๐ซ๐ž ๐†๐ข๐š๐ง๐ญ๐ฌ ๐๐ž๐ž๐ ๐‚๐จ๐ฆ๐›๐ข๐ง๐ž๐ ๐‘๐ž๐ ๐ฎ๐ฅ๐š๐ญ๐จ๐ซ๐ฒ/๐“๐ก๐ž๐ซ๐š๐ฉ๐ž๐ฎ๐ญ๐ข๐œ ๐€๐ซ๐ž๐š/๐€๐ˆ ๐’๐ค๐ข๐ฅ๐ฅ๐ž๐ ๐“๐š๐ฅ๐ž๐ง๐ญ
Read More »

Beyond the 16-Week Snapshot: Why Data Snapshots Mask the Reality of Chronic Therapy

Posted by Michael A. S. Guth on January 3rd, 2026

Beyond the 16-Week Snapshot: Why Data Snapshots Mask the Reality of Chronic Therapy In my independent review of the CARES-310 trial (Camrelizumab-Rivoceranib), I analyzed a common pitfall in modern drug development: the reliance on 16-week primary endpoints to justify long-term therapeutic narratives. While a 16-week data cut can deliver a clean p-value for a regulatory […]

Posted in AI Governance, Pharma and Medical Device, Regulatory Medical Writing Comments Off on Beyond the 16-Week Snapshot: Why Data Snapshots Mask the Reality of Chronic Therapy
Read More »
« Older Entries